At ACLA's annual meeting, a panel discussed how machine learning, artificial intelligence, telehealth, and at-home testing have gained traction throughout the laboratory industry.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.
The firm has received a supplemental approval that provides its customers with an option to purchase its IVD-labeled FLT3 mutation assay for in-house testing.
